Whitefort Capital Management, LP
CIK: 0001884931Latest portfolio: $391.2M · Q4 2025
Holdings
19
Total Value
$391.2M
New Positions
3
Closed Positions
2
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | I9DNARBUTUS BIOPHARMA CORP | 13,343,228 | $64.2M | 16.41% | — | |
| 2 | ROIVROIVANT SCIENCES LTD | 2,120,000 | $46.0M | 11.76% | -1,412,000 | |
| 3 | BALYBALLYS CORPORATION | 1,921,372 | $31.7M | 8.11% | +578K | |
| 4 | MRNAMODERNA INC | 1,000,000 | $29.5M | 7.54% | NEW | Put |
| 5 | OABIOMNIAB INC | 14,223,658 | $26.3M | 6.73% | — | |
| 6 | JOYYJOYY INC | 404,944 | $26.2M | 6.70% | — | |
| 7 | LQDALIQUIDIA CORPORATION | 752,700 | $26.0M | 6.64% | NEW | Call |
| 8 | TDAYUSA TODAY CO INC | 4,774,833 | $24.6M | 6.29% | +1.2M | |
| 9 | GNWGENWORTH FINL INC | 2,540,301 | $22.9M | 5.86% | -1,161,659 | |
| 10 | CDZICADIZ INC | 3,986,822 | $22.4M | 5.72% | — | |
| 11 | SOCSABLE OFFSHORE CORP | 1,910,793 | $17.2M | 4.41% | NEW | |
| 12 | OPK 3.75 01/15/29OPKO HEALTH INC | 9,350,000 | $12.5M | 3.19% | — | |
| 13 | QUREUNIQURE NV | 459,000 | $11.0M | 2.81% | NEW | |
| 14 | GQ9SPDR GOLD TR | 27,000 | $10.7M | 2.74% | — | Call |
| 15 | SGRYSURGERY PARTNERS INC | 600,000 | $9.3M | 2.37% | +229K | |
| 16 | OPKOPKO HEALTH INC | 4,253,340 | $5.4M | 1.37% | -646,660 | |
| 17 | VATEINNOVATE CORP | 743,000 | $3.4M | 0.86% | — | |
| 18 | KGKESTREL GROUP LTD | 160,916 | $1.6M | 0.42% | — | |
| 19 | NNAVWNEXTNAV INC | 47,264 | $337K | 0.09% | — |
Quarterly Changes
Sector Breakdown
Healthcare0.0% ($4.600429490263133e+23T)
Unknown0.0% ($641801.2T)
Communication Services0.0% ($2.6T)
Financial Services0.0% ($229.4B)
Consumer Cyclical0.0% ($31.7M)
Utilities0.0% ($22.4M)
Energy0.0% ($17.2M)
Industrials0.0% ($3.4M)
Technology0.0% ($337K)
Filing History
Fund Information
Whitefort Capital Management, LP is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $391.2M across 19 holdings. The largest position is ARBUTUS BIOPHARMA CORP (I9DN), representing 16.4% of the portfolio. Compared to the previous quarter, the fund opened 4 new positions and closed 3 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.